Nephrocare Health Services IPO Details
| Detail | Description |
|---|---|
| IPO Date | December 10, 2025 to December 12, 2025 |
| Listing Date | [.] |
| Face Value | ₹ 2 per share |
| Issue Price Band | ₹ 438 to ₹ 460 per share |
| Lot Size | 32 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 1,89,35,819 shares (aggregating up to ₹ 871.05 Cr) |
| Fresh Issue(Ex Market Maker) | 76,82,717 shares (aggregating up to ₹ 353.40 Cr) |
| Offer for Sale | 1,12,53,102 shares of ₹2 (aggregating up to ₹ 517.64 Cr) |
| Employee Discount | ₹ 41.00 |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 9,26,50,799 shares |
| Share Holding Post Issue | 10,03,33,516 shares |
About Nephrocare Health Services IPO
The size of the Nephrocare Health Services IPO is ₹871.05 crores, comprising a fresh issue of ₹353.40 crores and an offer-for-sale (OFS) component worth ₹517.64 crores. It is a book-built IPO with a price band set between ₹438 to ₹460 per share. The offer will open on 10 December 2025 and close on 12 December 2025, with an expected listing date of 17 December 2025 on BSE and NSE.
Company Background
Nephrocare Health Service Limited, which runs the brand NephroPlus, is headquartered in Hyderabad and is India's and Asia’s largest provider of dialysis services. Established in 2009, the organization offers comprehensive renal care such as hemodialysis and home dialysis, mobile dialysis and wellness support. It operates a network of more than 519 clinics both locally and abroad, such as in Uzbekistan, the Philippines and Nepal.
Operations And Product Range
Nephrocare runs a wide range of dialysis services, supported with 5,562 dialysis machines as of September 2025. The company serves a sizable portion of India’s dialysis population, with over 2.8M treatments served in FY2025. Its delivery model focuses on providing accessible, quality and affordable healthcare services through a pan-India network of in-hospital clinics, standalone clinics (Kidney Care Centers), management contract units and public-private partnership with state governments; Lifestyle disease management centers to provide holistic treatment.
Revenue Channels
The company derives its revenue from dialysis treatment services provided in the clinic network. It posted revenues of ₹769.92 crores and a PAT of ₹67.10 crores for FY2025, up from revenues of ₹574.72 crores and a PAT of ₹35.13 crores for FY2024. The business enjoys a high EBITDA margin and a scalable, asset-light model that enables rapid growth.
Management And Shareholding
Promoters And Shareholding
The promoters of the company are Investcorp Private Equity Fund II, Investcorp Growth Opportunity Fund, Edoras Investment Holdings Pte Ltd and Healthcare Parent, as well as other institutional investors that will sell shares through OFS. The promoters have a strong pre- and post-IPO stake of approximately 61-71%.
Board Members
The board is a combination of leadership team under the Chairman & MD Vikram Vuppala and independent & nominee directors from private equity and health care, ensuring robust governance & strategic guidance.
Nephrocare Health Services IPO Objectives
- • New dialysis clinics (to be opened with the proceeds generated from fresh issues to be raised through this public issue) – ₹129.11 crores.
- • Prepayment or scheduled repayment of debt – ₹136 crores. All other corporate purposes – for the balance amount on general corporate purposes.
- • Among other shareholders, including promoters and institutional investors, for providing liquidity to them.
Conclusion
As a direct play on the booming dialysis healthcare sector, supported by a large network, scalability, rising patient demand and financial growth, Nephrocare Health Service IPO is ready to offer an amazing opportunity to investors right from the start. With its leadership position and care protocols, the IPO has significant opportunities to leverage the increasing demand for renal care in India and specific overseas geographies.
Nephrocare Health Services IPO Financial Information
Latest Revenue
483.97
₹ Crore
Profit After Tax
14.23
₹ Crore
Net Worth
716.06
₹ Crore
Total Borrowing
207.04
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 2025 | 1,193.68 | 483.97 | 14.23 | 716.06 | 207.04 | ||||
| 31 Mar 2025 | 996.46 | 769.92 | 67 | 594 | 225.8 | ||||
| 31 Mar 2024 | 806.02 | 574.72 | 35.13 | 423.55 | 243.37 | ||||
| 31 Mar 2023 | 666.23 | 443.26 | -11.79 | 384.73 | 196.21 | ||||
| Amount in ₹ Crore | |||||||||
Nephrocare Health Services Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 13.45% |
| ROCE | 18.67% |
| RoNW | 13.19% |
| PAT Margin | 8.88% |
| EBITDA Margin | 22.05% |
| Price to Book Value | 7.72 |
| Market Capitalization | ₹4,615.34 Cr. |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 7.24 | 2.84 |
| P/E (x) | 63.52 | 162.19 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Largest dialysis network in India and Asia, with over 500 clinics serving more than 10% of India’s dialysis patients, supported by a scalable and asset-light business model leveraging hospital partnerships.
Strong clinical protocols, such as RenAssure® and Zero Infection Point (ZIP) kit, are achieving near-zero cross-infection rates and superior patient outcomes with advanced dialysis technologies.
Robust financial growth demonstrated by 34% revenue growth to ₹769.92 crore in FY2025 and healthy profitability, driven by high-margin margin scalable operations and diverse renal care services.
Download regulatory filings
Nephrocare Health Services IPO Timeline
| IPO Open Date | Wed, Dec 10, 2025 |
| IPO Close Date | Fri, Dec 12, 2025 |
| Tentative Allotment | Mon, Dec 15, 2025 |
| Initiation of Refunds | Tue, Dec 16, 2025 |
| Credit of Shares to Demat | Tue, Dec 16, 2025 |
| Tentative Listing Date | Wed, Dec 17, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Dec 12, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | 32 | ₹14,720 |
| Individual investors (Retail) (Max) | 13 | 416.00 | ₹1,91,360 |
| S-HNI (Min) | 14 | 448.00 | ₹2,06,080 |
| S-HNI (Max) | 67 | 2,144 | ₹9,86,240 |
| B-HNI (Min) | 68 | 2,176 | ₹10,00,960 |